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Systemic Sclerosis Mimics
Ondřej Kodet and Sabína Oreská
Abstract
Many clinical conditions are presenting with sclerosis of the skin and with tissue 
fibrosis. These conditions may be confused with systemic sclerosis (SSc, scleroderma). 
These diseases and disabilities are generally referred to as systemic sclerosis mimics or 
scleroderma-like syndromes. These disorders have very different etiologies and often 
an unclear pathogenetic mechanism. Distinct clinical characteristics, skin histology, 
and disease associations may allow distinguishing these conditions from systemic scle-
rosis and from each other. A histopathological examination with clinicopathological 
correlation for diagnosis is important to spare the patients from ineffective treatments 
and inadequate management. In this chapter, we discussed localized scleroderma, 
lichen sclerosus, nephrogenic systemic fibrosis, eosinophilic fasciitis, scleromyxedema, 
and scleredema. These are often detected in the primary care setting and referred to 
rheumatologists for further evaluation. Rheumatologists, or preferably in collabora-
tion with a dermatologist, must be able to promptly recognize them to provide valuable 
prognostic information and appropriate treatment options for affected patients.
Keywords: localized scleroderma, lichen sclerosus, eosinophilic fasciitis,  
nephrogenic systemic fibrosis, scleromyxedema, scleredema
1. Introduction
In this chapter, we discuss the groups of disorders classified as systemic sclerosis 
mimics. Localized and sometimes generalized skin stiffness is typical for this group 
of diseases. However, quite incongruous pathogenesis, underlying disease mecha-
nisms and distinct organ involvement are significantly different in these conditions. 
This chapter describes the pathogenesis, clinical manifestation, histopathology 
findings, and therapeutic possibilities of the most common diseases that may cause 
difficulties in the differential diagnosis of systemic sclerosis.
2. Localized scleroderma, morphea
2.1 Introduction
Localized scleroderma is a clinically distinct inflammatory disease, primarily 
of the dermis and also subcutaneous fat [1]. The inflammation leads to scar-like 
sclerosis. Inflammatory infiltrates and changes of small vessels are similar in 
morphea and systemic sclerosis (SSc), but morphea has more asymmetric or linear 
skin localization and distribution than SSc, which has symmetrical distribution. 
Generalized morphea can prevent and mimic diffuse cutaneous SSc, but this clini-
cal variant does not have Raynaud’s phenomenon, digital sclerosis and lung, and 
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gastrointestinal tract manifestation of the disease. Morphea is responsible for the 
morbidity of the patient such as skin tightness, joint mobility reduction leading to 
contractures, growth retardation, and pain [1–3].
2.2 Epidemiology
Morphea typically develops in adults, although morphea can occur at any age. 
The incidence of morphea is 3 per 100,000 people, and the prevalence of morphea 
increases with age. The mean age of disease onset is 45 years. Morphea is more 
prevalent in women than in men (2.6:1), except linear morphea, which has no 
gender preference [2–4].
2.3 Pathogenesis
The cause of the disease is unknown. Coexistence of various forms of scleroderma 
and the rare possibility of progression of localized scleroderma into SSc indicate 
that both types represent different manifestations of the same pathological process. 
Pathogenesis may be due to participation of environmental influences, immunologi-
cal disorders, and infections, e.g., association with Borrelia burgdorferi [3]. Sclerosis 
of the skin is induced by vascular damage, activated T cells, and accented connective 
tissue production by dermal fibroblasts. Vascular changes represent a reduction in 
the number of capillaries. Enhanced production of collagen and other extracellular 
matrix proteins and components is induced by T-cell-derived cytokines, interleukin 4 
(IL-4), IL-13, and transforming growth factor beta (TGF-β) [3, 5, 6].
2.4 Clinical features
Morphea can be divided into several clinical groups: plaque-type morphea, lin-
ear morphea, generalized morphea, deep morphea, nodular morphea, and guttate 
morphea. Patient with morphea does not have involvement of internal organs and 
Raynaud’s phenomenon. Some patients may have involvement of muscles, tendons, 
and joints or neurological or ophthalmological symptoms which depend more likely 
on anatomical site, e.g., in a patient with linear morphea [2].
2.5 Plaque-type morphea, circumscribed morphea
Plaque-type morphea is the most common variant, characterized by a slightly 
elevated, edematous, erythematous, or violaceous and livid plaque with oval to round 
or centrifugal distribution (Figure 1). The developmental stage of the disease may 
influence the clinical features: (i) inflammatory, (ii) sclerotic, and (iii) atrophic [1, 2].
Figure 1. 
Plaque-type morphea, lesion on the right side of the trunk. Plaques are surrounded by a dark red rim on the 
periphery with a yellowish white color center of the lesion as a result of the increasing deposition of connective tissue.
3Systemic Sclerosis Mimics
DOI: http://dx.doi.org/10.5772/intechopen.88546
In the inflammatory phase, these are delimited striated skin plaques with 
the accentuated surface by skin pores, which resemble “orange peel” due to the 
edema of the corium expanding the follicular orifice. Plaques are surrounded by 
a violaceous rim on the periphery, indicating the active inflammatory stage of the 
disease. A yellowish-white color develops in the center of the lesion as a result of the 
increasing deposit of connective tissue [3]. In the sclerotic phase, the inflammatory 
border is absent. The skin of the lesion is smooth, shiny, and difficult or unable to 
be shaken. In the final (atrophic) phase, induration disappears; the plaques are soft, 
slightly sloping for skin and subcutaneous atrophy, and mostly gray-brown pig-
mented. Circumscribed morphea usually presents as single or multiple skin lesions. 
It is generally asymptomatic, but the central portion of the progressing lesion starts 
to get rigid and may be slightly painful [2, 3].
A different manifestation of morphea can be present. Guttate morphea presents 
as multiple rather superficial and nummular plaques (Figure 2).
Deep morphea represents sclerosis that affects the primarily deep parts of the 
dermis and subcutaneous fat (Figure 3).
Figure 2. 
Guttate morphea, multiple nummular lesions on the right thigh.
Figure 3. 
Deep morphea, the affection of the front of the right thigh, mapping distribution of erythematous and whitish 
parts with visible scarring.
New Insights into Systemic Sclerosis
4
2.6 Linear morphea
Linear morphea is similar in the clinical feature to circumscribed morphea but 
with a linear distribution. Linear morphea initially starts as a linear erythematous 
streak or harmless lesion that later forms a scar-like band (Figure 4).
This scar-like band significantly impairs the mobility of the affected limb. 
Linear morphea can affect the underlying fascia, the muscle, and tendons. Linear 
morphea that transcends joints can significantly reduce movement and lead to 
developmental limb defects in children. Rarely, it can form bizarre configurations 
when copying Blaschko’s lines [1, 3, 7].
2.7 “En coup de sabre”
The “en coup de sabre” represents a linear type of morphea of the head. This mor-
phea is unilateral and extends from the forehead into the frontal scalp (Figure 5).
It usually starts as a small plaque with the surrounding inflammatory erythematous 
rim. Parry-Romberg syndrome is a rare variant of linear morphea of the forehead and 
scalp, with progressive loss of subcutaneous fat, with a smaller share of sclerosis [3, 8, 9].
Figure 4. 
Linear morphea, linear distribution of plaques, leading to atrophic changes in the affected limb.
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2.8 Generalized morphea
Generalized morphea begins as multiple plaque-type morphea on the trunk. 
This clinical variant is defined by the presence of ≥4 plaques involving at least two 
different anatomic sites (Figure 6).
In contrast to systemic sclerosis, generalized morphea does not present with 
sclerosis primarily involving acral skin or sclerodactyly, but this anatomical site 
can also be affected [10]. Apart from the skin, generalized morphea can also 
affect the subcutis and fascia, and be accompanied by slight changes in internal 
organs (especially the gastrointestinal tract and lungs) and the formation of joint 
contractures with mostly secondary joint involvement and movement limitation  
[11, 12]. Carapace-like tightening of the chest, can reduce breathing and cause 
swallowing difficulties.
2.9 Laboratory findings
Laboratory abnormalities are typically associated with generalized and linear 
morphea, but some patients with morphea have elevated antinuclear antibody 
(ANA). Reported rates of ANA positivity among patients with morphea range 
from 18 to 68%. Other autoantibodies that are detected less frequently than ANA 
in patients with morphea include anti-single-stranded DNA (ssDNA), anti-double-
stranded DNA (dsDNA), antihistone, anti-topoisomerase IIα, antiphospholipid, 
and rheumatoid factor [1, 13].
2.10 Histopathology
The histopathological findings depend on the stage of the disease and area where 
the biopsy was taken (inflammatory border or central sclerotic lesion). Biopsy 
specimens for histology must include subcutaneous fat (Figure 7).
Biopsies performed from inflammatory lesions demonstrate an interstitial 
and perivascular inflammatory cell infiltrate composed primarily of CD4+ T 
Figure 5. 
“En coup de sabre” as linear morphea of the head. Linear scarring lesion on the forehead with an erythematous 
rim spreading to the scalp.
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Figure 7. 
Deep skin biopsy to subcutaneous fat after formaldehyde fixation.
cells, eosinophils, plasma cells, and mast cells. Inflammation may extend into 
the subcutaneous tissues. Furthermore, tissue edema, enlarged tortuous vessels, 
and thickened collagen bundles may be observed. Biopsy from a sclerotic lesion 
Figure 6. 
Generalized morphea begins as multiple-plaque-type morphea on the abdomen, circularly affecting breasts and 
the neck. In the margins, lesions are with a rim of erythema, indicating the inflammatory stage of the disease.
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demonstrates homogenization of the papillary dermis and thickened collagen 
bundles extending into the reticular dermis or beyond (Figure 8). In biopsy from 
deep morphea, the deep reticular dermis, subcutis, and fascia show sclerotic 
changes [14].
2.11 Differential diagnosis
A number of other disorders can present with clinical features that resemble 
morphea. Generalized morphea is necessary to distinguish from systemic sclerosis 
or scleredema diabeticorum. In addition to the skin sclerosis, systemic sclerosis 
generally begins with the Raynaud’s phenomenon, and patients commonly exhibit 
initial puffiness and eventual sclerosis in the fingertips (sclerodactyly), usually 
accompanied by nail fold capillary changes. These changes are absent in patients 
with morphea. The differential diagnosis of plaque-type morphea includes lichen 
sclerosus, morpheaform basal cell carcinoma, and postirradiation morphea. 
Furthermore, we need to think of lipodermatosclerosis as fibrosing panniculitis 
with typical localization on the lower extremities or eosinophilic fasciitis. In some 
cases of limb involvement, pretibial myxedema or Lyme disease (acrodermatitis 
atrophicans) must be excluded [1, 13, 14].
2.12 Treatment
A variety of treatment options are available for patients with active lesions of 
morphea; however, evidence in support and success of these therapeutics modali-
ties is limited. The expected outcome of successful therapy for morphea is not 
a complete healing or normal skin texture. In patients with progressive disease, 
successful treatment presents stopping the formation of new lesions and limiting 
the spreading of the disease [1, 15].
Figure 8. 
Biopsy from a sclerotic lesion demonstrates homogenization of the papillary dermis and thickened collagen 
bundles extending into the reticular dermis.
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2.13 Topical and intralesional treatment
Topical therapies are unlikely to be effective for the disease involving the 
subcutis or deeper tissues and are not useful for preventing the development of new 
lesions in patients with rapidly progressive disease. Topical tacrolimus as tacroli-
mus 0.1% ointment may be effective for active, inflammatory morphea [16]. High 
potency topical and intralesional corticosteroids are widely used for the treatment 
of morphea; however, no formal studies have documented their efficacy. Topical 
vitamin D—vitamin D as topical calcipotriene 0.005% ointment—may inhibit 
effects on fibroblast proliferation, collagen synthesis, and T-cell activation. In some 
clinical studies, an improvement on this therapy was noted in limited numbers of 
patients [15, 17].
Imiquimod is a topical immunomodulator that induces interferon-gamma, a cytokine 
that inhibits TGF-beta and the production of extracellular matrix proteins. Imiquimod 
also downregulates the profibrotic cytokine IL-4. Limited data suggest that imiquimod is 
effective in some patients with plaque-type morphea [18].
It is possible to use phototherapy in patients with sclerotic diseases like morphea. 
Longer wavelengths of light as ultraviolet A (UVA) (320–400 nm) are capable of 
greater depth of penetration into the skin, and most studies of UV phototherapy in 
sclerotic skin disease have focused on the use of UVA light (320–400 nm). Fewer 
data are available on the use of PUVA therapy (a combination of UVA and topical or 
oral use of psoralens) and ultraviolet B (UVB) light (290–320 nm). Phototherapy 
is unlikely to be effective for morphea with deep involvement (subcutis, fascia, or 
muscle) and should not be considered as primary therapy alone [19].
2.14 Systemic treatment
Patients with the progressive disease require systemic therapy with methotrexate 
or corticosteroids. Methotrexate is the most appropriate systemic therapy for mor-
phea. In patients with acute generalized or rapidly progressive disease, we combine 
treatment with systemic corticosteroids. Methotrexate is typically given for at least 
6–12 months with a weekly dose of 15–25 mg. The systemic corticosteroids are usu-
ally tapered and discontinued after 3–4 months or pulse intravenous therapy is used 
instead (500–1000 mg of intravenous methylprednisolone sodium succinate for 3 
consecutive days/month) [15, 20].
3. Morpheaform inflammatory syndromes/conditions
Some diseases and disorders with acrosclerosis and Raynaud’s phenomenon 
have a clinical presentation similar to localized scleroderma. The etiology of these 
disorders is diverse and includes, e.g., secondary sclerosis after exposition to 
bleomycin, vinyl chloride, L-tryptophan, or toxic oils. Sclerosis can also be induced 
by endogenous metabolites, by x-irradiation, or during chronic graft-versus-host 
disease (GVHD) (Figure 9). Morphea-like lesion, eosinophilic fasciitis, and lichen 
sclerosus can also be observed in these patients [21].
3.1 Lipodermatosclerosis
3.1.1 Introduction
Typical changes associated with chronic venous insufficiency include ery-
thema, induration, and hemosiderin pigmentary changes. But a variety of clinical 
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appearances and histopathologic findings also include sclerosis, or sclerosing 
panniculitis. The various manifestations of this panniculitis have been consolidated 
under the heading of lipodermatosclerosis or sclerosing panniculitis [22].
Lipodermatosclerosis typically manifests in patients, usually in women over the 
age of 40 years with chronic venous insufficiency as a result of chronic hypoxia. 
Venous hypertension leads to a compromised ability to reduce foot vein pressure 
during exercise. This change results in increased capillary permeability, with leak-
age of fibrinogen, with subsequent polymerization leading to formation of fibrin 
plaques around vessels. There may also be an abnormal regulation of angiogenesis 
in a patient with lipodermatosclerosis. For example, increased expression of 
vascular endothelial growth factor receptor 1 (VEGFR-1) can be a result of VEGF-
mediated angiogenesis. Another factors may include local stimulation of collagen 
and obesity [23, 24].
3.1.2 Clinical features
Sclerosis affects the acral parts of the lower limbs symmetrically. The acute 
and progressive phase of lipodermatosclerosis presents with pain, erythema, and 
the formation of induration on the affected area of lower limbs. In the chronic 
phase, sclerosis of the dermis and subcutis is typically present, and sclerosis results 
in induration that is more sharply demarcated from the adjacent normal skin 
(Figure 10). Other gravity dependent sites such as the lower aspect of the abdomi-
nal pannus can also develop lipodermatosclerosis. At this point, the changes are 
relatively diffuse. Hyperpigmentation due to hemosiderin deposition or chronic 
ulceration of the lower limbs may also be present [22].
Figure 9. 
Morphea-like lesion in a patient with GVHD. Post-inflammatory hyperpigmentation with whitish areas of 
sclerotic skin affecting the left thigh.
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3.1.3 Histopathology
Early lesions show mid-lobular panniculitis, a lymphocytic infiltrate in the septa, 
variable degrees of capillary congestion, and extravasation of erythrocytes with hemo-
siderin deposition. Chronic lesions show septal sclerosis and membranocytic change 
with a marked reduction in inflammation or lymphocytic infiltrate [25, 26].
3.1.4 Differential diagnosis
In differential diagnosis, it is necessary to distinguish inflammatory changes such 
as cellulitis and erysipelas but also erythema nodosum or erythema induratum. As 
induration develops and progresses, differentiation from morphea and scleromyx-
edema may be necessary. In morphea, subcutaneous involvement is predominantly 
septal, and lipophagic and lipodystrophic changes are not typically present [22, 25].
3.1.5 Treatment
Leg elevation and consistent compression therapy are crucial for the treatment 
of lipodermatosclerosis. Traditional anti-inflammatory therapies are usually inef-
fective, but topical or intralesional corticosteroids (e.g., triamcinolone 5–10 mg/cc) 
may bring relief and improvement with compression therapy [27].
3.2 Injection of vitamin K
Oil-soluble injection of vitamin K may be responsible for the eosinophilic 
reaction of the deep part of the dermis and subcutaneous fat, which may resemble 
localized eosinophilic fasciitis with similar clinical manifestation as deep morphea. 
This inflammation can result in dermal and subcutaneous atrophy [28].
3.3 Vaccination-associated morphea
Circumscribed morphea and deep morphea have been described after intramus-
cular injections of different types of vaccines. The etiology and antigens responsible 
for this type of inflammation have not been reliably elucidated [29].
Figure 10. 
Lipodermatosclerosis in a patient with chronic venous insufficiency. In this case erythema and sclerotic whitish 
induration on the medial part of the shank with the border of hemosiderin pigmentary changes are present.
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3.4 Paraffin and silicone injections or silicone implants
The leak of silicone from implants and silicone or paraffin injection after recon-
structive or plastic surgery induce chronic inflammation that results in localized 
morphea-like lesion. The contribution to the induction of SSc, eosinophilic fasciitis, 
or mixed connective tissue disease has also been discussed [30].
3.5 Porphyrias
Porphyria cutanea tarda can lead to a morphea-like lesion and scarring in the 
chronic sun (UV)-exposed sites, such as the face, scalp, dorsal part of the hands, 
and upper part of the chest [31].
3.6 Radiation-induced morphea
X-irradiation can induce sclerotic, chronic erythematous, and secondary 
pigmented lesions typically in a patient after irradiation of the chest and axillary 
region for breast carcinoma (Figure 11). The morphea-like lesions can start several 
years after radiation [32].
3.7 Differential diagnosis
The differential diagnosis is summarized in this paragraph, but the most impor-
tant entity in the differential diagnosis of SSc or localized scleroderma is lichen 
sclerosus et atrophicus and scleromyxedema. Absence of overall symptoms and 
organ involvement is crucial [21].
4. Lichen sclerosus
Lichen sclerosus et atrophicus is an inflammatory disease, primarily of 
the superficial dermis or mucosa, which leads to white scar-like atrophy. 
Extragenital lichen sclerosus may itch and be cosmetically annoying. Genital 
lichen sclerosus causes dryness and persistent pruritus. Genital lichen leads to 
progressive atrophy, and functional impairment, which significantly reduces the 
quality of life.
Figure 11. 
Morphea-like lesion in a patient after x-irradiation for breast carcinoma. The erythematous and sclerodermic 
lesion on the right breast.
New Insights into Systemic Sclerosis
12
4.1 Epidemiology
Prevalence of lichen sclerosus is unknown. This chronic disease occurs at all ages 
with a similar incidence in all races. The ratio of occurrence in men and women var-
ies considerably, but in both sexes, the most affected area is the anogenital region 
(about 85% of patients, in women usually as a vulvar disease) [33, 34].
4.2 Pathogenesis
Association with the MHC class II antigen HLA-DQ7 was observed, but the spe-
cific genetic predisposition is unknown. Unspecific inflammation seems to be essen-
tial for the initiation and also the progression of lichen sclerosus. Autoantibodies 
such as those against the extracellular matrix protein 1 (ECM-1) were found in 80% 
of patients with lichen sclerosus. Moreover, in female patients with lichen sclerosus, 
there is a higher prevalence of autoimmune diseases (especially autoimmune thyroid 
disease) and ANA positivity than in male patients with lichen sclerosus [34–36].
4.3 Clinical features
Lichen sclerosus manifests by polygonal, bluish-white, shiny, slightly elevated 
maculopapules with a pointed follicular bounds of hyperkeratoses, which may be 
solitary or in groups. This skin lesion can be bounded with an area of erythema. The 
solitary lesion enlarges to plaques and to the scar-like lesion with a rough surface 
and skin atrophy (Figure 12).
More rarely, blistering with possible hemorrhagic content can be present 
(Figure 13). Extragenital predilection sites include supraclavicular localization, 
under the breasts, cubit, groin, loose wrist, and cross. Symptoms of extragenital 
lichen sclerosus are dryness and pruritus.
However, lichen sclerosus most frequently affects the anogenital region. In 
women, it typically affects the vulva and the perianal localization in figure-of-eight 
configuration (Figure 14). Genital lichen sclerosus begins as slightly elevated lesion 
of erythema, sometimes with erosions. During the chronic stage of the disease, the 
skin becomes shiny, sclerotic, and also hypopigmented. The scarring may affect the 
clitoris and labia, and disability may be significant or even make the sexual inter-
course impossible. Although the disease may be symptom-free, it frequently causes 
severe pruritus and pain is a typical symptom. Another symptom may be dysuria or 
pain upon defecation [34, 37].
Figure 12. 
Extragenital lichen sclerosus, slightly elevated plaque with scar-like presentation, with a whitish erythematous 
rim and skin atrophy.
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4.4 Histopathology
Lichen sclerosus has a specific histopathological pattern. Initially, superficial 
dermal edema is associated with a band-like lymphocytic infiltrate. The epidermis 
is thinned and atrophic, with orthohyperkeratosis and vacuolar degeneration of the 
basal layer. Hyperkeratosis is especially pronounced at follicular openings and may 
lead to plugging. Vacuolar degeneration of the basal layer and flattening of the rete 
ridges predispose to the development of blisters, which may become hemorrhagic. 
The most important changes are found in the superficial dermis with the presence 
of homogenized collagen (Figure 15). Loss of elastic fibers is typical for lichen 
sclerosus and is not observed in morphea [38–40].
Figure 13. 
Extragenital lichen sclerosus, whitish plaque with blisters and crusts. Blisters resemble hemorrhagic-like content.
Figure 14. 
Genital lichen sclerosus affects the labia minora, clitoris, and vulval vestibule. Whitish and erythematous 
plaques are also present in the labia majora, the perineum, and the perianal region.
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4.5 Differential diagnosis
The differential diagnosis of extragenital lichen sclerosus includes morphea, 
vitiligo, tinea versicolor, anetoderma, or cutaneous lymphoma. In the case of 
genital lichen sclerosus, erosive lichen planus and erythroplasia of Queyrat must 
be considered.
Sometimes it is not possible to distinguish morphea from lichen because clinical 
and especially histopathological findings of both diseases can also be present in one 
patient or one biopsy [34].
4.6 Treatment
Topical medications, phototherapy, and systemic therapy have been used 
for the treatment of lichen sclerosus. The effect of topical corticosteroids was 
reported especially in genital lichen sclerosus, but mitigation has also been 
demonstrated in extragenital lichen. Effect of topical corticosteroid therapy has 
been reported in randomized treatment and retrospective studies. Phototherapy 
is preferred second-line treatment for patients with limited disease that can-
not be effectively treated with topical corticosteroids. An alternative to topical 
corticosteroids is the use of calcineurin inhibitors pimecrolimus and tacrolimus 
despite concerns of possible increase of development of squamous cell carcinoma 
or reactivation of HPV [15, 37, 41].
The use of systemic therapy is limited to a small group of patients with progres-
sive worsening of extragenital lichen sclerosus that failed to respond to a potent 
topical corticosteroid and phototherapy. For systemic therapy, methotrexate 
(15–20 mg/week) and systemic corticosteroids (1 g of intravenous methylpredniso-
lone sodium succinate for 3 consecutive days/month) can be used [42].
Figure 15. 
Skin biopsy of extragenital lichen sclerosus where atrophic thinned epidermis and mild vacuolar degeneration 
of the basal layer are present. In the superficial dermis, homogenized collagen with perivascular lymphocytic 
infiltrates can be found.
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5. Eosinophilic fasciitis
Eosinophilic fasciitis is a relatively recently described disease, characterized 
by fibrosing induration of the extremities and peripheral eosinophilia. In many 
patients strenuous physical activity precedes the development of this condition.
5.1 Clinical feature
Initial clinical manifestation includes painful edema of the extremities, which 
progresses to fibrosis and pseudo-inflammatory appearance (Figure 16). The mani-
festation of the disease is typically symmetrical on extremities without involvement 
of the hands, feet, and face [43].
Laboratory findings include elevation of ESR, hypergammaglobulinemia and 
peripheral eosinophilia which can be present in the early phase of the disease. ANA 
titer and complement level are usually normal. Pancytopenia, anemia, thrombo-
cytopenia, myeloproliferative disorders, and monoclonal gammopathy have been 
reported in association with eosinophilic fasciitis. The diagnosis of eosinophilic 
fasciitis is established via fascial biopsy and/or by MRI [44].
5.2 Histopathology
Histologically eosinophils and mast cells are present, and dermal fibrosis with 
patchy infiltrates composed of lymphocytes and plasma cells are also present. 
In deep biopsy thickening of the fascia is typical, which may be 10–50 times the 
normal width [44].
5.3 Treatment
Once the diagnosis of eosinophilic fasciitis is established via fascial biopsy and/
or MRI, prompt treatment is essential to preserve mobility and function and pre-
vent joint contractures. Prompt therapy with oral corticosteroids (e.g., prednisone 
1–2 mg/kg daily) is usually necessary for reduction or cessation of rapid disease 
progression and as prevention of mobility reduction and development of joint 
contractures. The response is typically noted within the first few weeks, and clinical 
improvement may be seen over several months. Alternatively, hydroxychloroquine, 
cyclosporine, dapsone, methotrexate, PUVA, or infliximab may be used alone or in 
combination with prednisone. Phototherapy as UVA1 can also be beneficial [45].
Figure 16. 
Eosinophilic fasciitis with initial clinical manifestation of progressive fibrotic changes with pseudo-
inflammatory appearance.
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6. Nephrogenic systemic fibrosis
Nephrogenic systemic fibrosis is most often observed in middle-aged adults 
but has also been described in children and elderly patients. There is no gender or 
race predilection. Renal dysfunction and exposure to gadolinium-based contrast 
medium play a crucial role in the pathogenesis. Although the context use of the 
gadolinium in a patient with renal dysfunction is irrefutable, the mechanisms of 
fibrosis are still unknown [46, 47].
6.1 Clinical features
This disorder presents with large and thick, indurated plaques distributed 
symmetrically on the extremities and trunk. The skin lesions are irregular and 
erythematous with a tendency to develop hyperpigmentation. The manifestation 
on the extremities often results in joint contractures. The condition is frequently 
associated with considerable pain and loss of mobility. Extracutaneous manifesta-
tions include yellow scleral plaques and systemic fibrosis with involvement of the 
heart, lungs, and also skeletal muscles [48, 49].
6.2 Histopathology
A deep biopsy is necessary for diagnosis. Histologic features include increased 
dermal fibroblast-like cells with positivity for CD34 and procollagen I. Haphazard 
arrangement of thickened collagen bundles is also present. Furthermore, vascular 
proliferation and mucin deposition may also be present.
6.3 Treatment
Nephrogenic systemic fibrosis is refractory to treatment with corticosteroids 
and other immunosuppressive drugs. There have only been case reports of improve-
ment with imatinib, rapamycin, phototherapy UVA1, PUVA, or plasmapheresis. 
Improvement in renal function after renal transplantation may improve this type of 
fibrosis [49].
7. Stiff skin syndrome
This dysfunction may be hereditary as a congenital disorder or acquired dur-
ing early childhood. Familiar hereditary subtype is caused by heterozygosity for 
a mutation in the gene that encodes fibrillin-1 (FBN1). Dysfunction of this gene 
results in the production of giant collagen fibrils in the affected fascia [50].
7.1 Clinical features
Stiff skin syndrome is characterized by “rock hard” induration and thickening 
of the skin and subcutaneous tissues. Typical manifestation is on the buttocks 
and thighs with mild hypertrichosis without affecting the inguinal folds. This 
disorder does not affect the hands and feet. The condition is stable or slowly 
progressive, and abnormalities of internal organs are not typically observed. In 
differential diagnosis the disease may resemble scleredema, deep morphea, or 
linear scleroderma [51].
17
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7.2 Histopathology
Histologically, significant thickness of fascia with deposition of hyaline without 
an associated inflammatory infiltrate can be found. Thickened collagen bundles and 
mucin deposition may be present in the dermis. The epidermis and papillary dermis 
are mostly without any pathologies [52].
7.3 Treatment
Treatment of stiff skin syndrome is very difficult, and no effective treatments 
have been reported. Physical therapy and regimen measures for the patient can help 
to prevent progressive joint contractures and immobility [51, 52].
8. Scleromyxedema
Scleromyxedema is a chronic idiopathic disorder characterized by papules 
and lesion of induration with dermal mucin deposition and with an increase 
of dermal collagen resulting in skin sclerosis. Many patients with scleromyx-
edema have monoclonal gammopathy, with systemic or lethal manifestations. 
Scleromyxedema represents a generalized variant that needs to be distinguished 
from localized lichen myxedematosus (variant without sclerosis and parapro-
teinemia) [53].
8.1 Pathogenesis
The exact pathogenesis of scleromyxedema is unknown, typically affecting 
middle-aged adults of both sexes equally. The role of the associated monoclonal 
gammopathy remains a matter of debate, because, for example, paraprotein levels 
do not correlate with progression of the disease. But clinical remission of sclero-
myxedema, during the reduction of paraprotein, that follows after autologous 
hematopoietic stem cell transplantation was described [53, 54].
8.2 Clinical features
In the clinical manifestation of scleromyxedema, typically widespread and sym-
metrically firm, waxy, and closely aligned papules are present (Figure 17).
Figure 17. 
Scleromyxedema. Numerous skin-colored papules of the neck.
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Predilection localizations include the head and neck, upper trunk, forearms, 
and thighs and the proximal parts of fingers. The surrounding skin is shiny with 
sclerodermoid appearance. Deep longitudinal furrowing is typically involved on the 
glabella. Strong and rigid infiltrates of the face can result in the face of a lionlike face. 
As the condition progresses, erythematous and infiltrated plaques may be present 
with skin stiffening, sclerodactyly, and decreased motility of the mouth and joints.
Scleromyxedema is almost always associated with paraproteinemia. The mono-
clonal gammopathy is usually IgG and the light chains are more commonly lambda. 
Patients with scleromyxedema can have a number of internal manifestations, such 
as dysphagia, proximal muscle weakness due to myositis, peripheral neuropathy, 
arthropathies, carpal tunnel syndrome, restrictive or obstructive lung disease, and 
also scleroderma-like renal disease [54].
8.3 Histopathology
Scleromyxedema is characterized by diffuse deposits of mucin in the upper and 
middle part of the reticular dermis, increase in collagen deposition in the reticular 
dermis, and significant proliferation of irregularly distributed fibroblasts. Mucin 
may fill the walls of myocardial blood vessels as well as vessels of the kidney, the 
pancreas, adrenal glands, nerves, or lymph nodes [55].
8.4 Differential diagnosis
The primary differential diagnosis of scleromyxedema includes systemic 
sclerosis and scleredema. Other conditions in differential diagnosis with possible 
presence of mucin in the biopsy include nephrogenic systemic sclerosis. Differential 
diagnosis of leonine facies includes, for example, lepromatous changes, leishmani-
asis, cutaneous lymphoma (T cell, rarely B cell), an actinic reticuloid as chronic 
actinic dermatitis, systemic amyloidosis, nodular mastocytosis, or sarcoidosis [53].
8.5 Treatment
Recommendations are still based on case reports and open-label small case 
series. Many chemotherapeutics, primarily melphalan, cyclophosphamide, metho-
trexate, or chlorambucil, have been tried, with no better results but with the risk 
of significant side effects. IVIg, alone or in combination with systemic medications 
such as thalidomide or systemic corticosteroids, may be administered as first-line 
therapy for cutaneous involvement and also systemic manifestations, including 
the dermatoneurological syndrome. Additional therapies include PUVA, UVA1, 
systemic retinoids, cyclosporine, electron beam radiation, plasmapheresis, and 
extracorporeal photochemotherapy with variable and unpredictable results [56].
9. Scleredema adultorum of Buschke
Scleredema is typically symmetrical diffuse induration and sclerosis of the 
upper part of the body especially of the trunk due to thickened dermis with mucin 
deposition and with relationship to diabetes mellitus.
9.1 Pathogenesis
Scleredema is a relatively unusual and rare disease that affects patients of all 
races. The typical form that is associated with diabetes mellitus is more prevalent in 
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men, while other forms are seen more commonly in women. Irreversible glycosyl-
ation of collagen and resistance to degradation lead to an accumulation of collagen 
deposition. Furthermore, stimulation by insulin, microvascular changes and dam-
age, and hypoxia during diabetes mellitus may increase the synthesis of collagen 
and mucin which result in a dermal deposition of collagen [57].
9.2 Clinical features
Scleredema adultorum may be divided into three clinical types of scleredema. 
The first type affects primarily children and middle-aged women. It is preceded by 
fever, malaise, and an infection (usually streptococcal) of the upper or lower respi-
ratory tract. The localization of this type is the cervicofacial region with extension 
to the trunk and proximal upper limbs. The cervicofacial region typically affects the 
perioral localization with difficult opening of the mouth and hindered swallowing. 
This type usually resolves spontaneously. The second type shares the same clinical 
features as the first but with very slow manifestation and is more commonly associ-
ated with a monoclonal gammopathy [58].
The third type typically affects obese middle-aged men with insulin-dependent 
diabetes (scleredema diabeticorum). Sclerosis usually starts very slowly and the 
involvement is persistent. Affected skin is usually erythematous and indurated with 
typical localization of the posterior region of the neck and the back (Figure 18). 
The affected skin has peau d’orange appearance. In all three forms, systemic mani-
festations such as serositis, myositis, dysarthria, dysphagia, parotitis, and ocular 
and cardiac abnormalities may be present [57–59].
9.3 Histopathology
The main histopathological feature is the thickening of the reticular dermis, 
with atypical large collagen bundles. Mucin deposition is also present among 
separated collagen bundles. There is no increase in the number of fibroblasts, but 
the elastic fibers are significantly reduced in number. Mucin is also accumulated in 
the skeletal muscle and in the heart.
Figure 18. 
Scleredema adultorum with typical localization of the posterior region of the neck and the back with affected 
erythematous and indurated skin.
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9.4 Treatment
Scleredema which is associated with streptococcal infections is self-limited, 
thus no therapy is needed. Therapy of scleredema associated with diabetes or a 
monoclonal gammopathy is more difficult, and no specific treatment is available. 
Phototherapy as UVA1 or PUVA is the first-line therapy. Systemic and intralesional 
corticosteroids, intralesional hyaluronidase, antibiotics, methotrexate, cyclospo-
rine, pulse therapy with cyclophosphamide plus oral corticosteroids, tamoxifen, 
and allopurinol have all been tried, with variable results [58, 59].
10. Endocrine disorders
Some endocrine disorders like diabetes mellitus and hypothyroidism can be accom-
panied with skin induration and sclerotic changes and may thus be a diagnostic problem 
for both systemic sclerosis and its localized forms. Endocrine disorders include sclero-
dactyly as “diabetic cheiroarthropathy” and myxedema in hypothyroidism.
10.1 Diabetic cheiroarthropathy
Diabetes mellitus is associated with a wide variety of rheumatologic mani-
festations which can significantly affect a patient’s quality of life. One of these 
manifestations includes diabetic cheiroarthropathy which is associated with type 
I diabetes. Diabetic cheiroarthropathy affects typically the hands. It is postulated 
to result from increased glycosylation of collagen in the skin and is associated with 
retinopathy, nephropathy, and duration of the diabetes [60, 61].
10.1.1 Clinical features
Clinical features include thickened skin and limited joint mobility of the hands 
and fingers, leading to flexion contractures and an inability to approximate the 
palmar surfaces of the hands and fingers. Sometimes ischemic ulceration and 
calcinosis cutis can be present.
Treatment relies primarily on glycemic control and on nonsteroidal anti-
inflammatory drugs and physical therapy with physiotherapy. With improved 
glycemic control, the symptoms and signs can be ameliorated and complete reversal 
is possible [61].
10.2 Mucinoses associated with thyroid dysfunction
Pretibial myxedema is characterized by cutaneous induration of the shins 
due to mucin deposition. It is often associated with hyperthyroidism most com-
monly due to Graves’ disease. Localized myxedema with goiter, exophthalmos, 
and thyroid acropachy are typical signs of Graves’ disease. Pretibial myxedema 
is found in 1–5% of patients with Graves’ disease and in up to 25% of those with 
exophthalmos [62].
10.2.1 Localized myxedema
10.2.1.1 Clinical features
Localized myxedema presents as erythematous, yellowish or skin-colored waxy 
induration in a form of a nodulus or plaques. Typical localizations include ventral or 
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anterolateral parts of the lower legs or the feet (Figure 19). In early phases localized 
myxedema can also present as a diffuse non-pitting edema of the shins or feet that 
evolves into lymphedema. Even more rarely, localized myxedema affects the face, 
shoulders, upper extremities, the lower abdomen, scars, or donor graft sites. Large 
plaques are often painful and pruritic. When present, hypertrichosis and hyperhi-
drosis are confined to the pretibial myxedematous skin [63, 64].
10.2.1.2 Treatment
First-line therapy such as topical corticosteroids or their application under 
occlusive dressings can be used. In some cases intralesional injection of corticoste-
roids can be effective. In a patient with lymphedema, medical treatments including 
IVIg, rituximab, plasmapheresis, and their combination with surgical treatment 
may have some benefit [63, 65].
10.2.2 Generalized myxedema
Generalized myxedema is a manifestation of hypothyroidism where mucin is 
deposited in the dermis, leading to waxiness of the skin. This condition is caused by 
a quantitative or functional deficiency of thyroxine. Impaired degradation of mucin 
and/or increased synthesis is suggested as the main cause.
10.2.2.1 Clinical features
The typical skin is pale, cool, waxy, and dry. Anhidrosis as an absence of sweat-
ing may lead to ichthyosis or eczema “craquelé.” Hair and nails are dry and diffuse 
Figure 19. 
Pretibial myxedema presents as erythematous waxy induration and nodulus on the ventral part of the shank.
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non-scaring alopecia is also common. A yellowish hyperkeratosis of the palms may 
be present. Sometimes purpura on the extremities and skin xanthomas may be 
observed [66].
10.2.2.2 Treatment
Early treatment of hypothyroidism is crucial for reduction or cessation of skin 
involvement and overall symptoms of the disease.
11. Amyloidosis
The cutaneous amyloidosis represents a heterogeneous group of conditions in 
which amyloid, as a fibrillar material that can result from the pathological degrada-
tion of various proteins, is deposited in the skin. In primary cutaneous amyloidosis, 
the deposits are derived from keratin (macular, lichen, biphasic) or immunoglobu-
lin light chains (nodular) [67].
The specific cutaneous lesions of primary systemic amyloidosis are waxy, translu-
cent, or purpuric papules, nodules, and plaques. Amyloid infiltration of the skin may 
produce thickening and stiffness. Typical localization may be on the limbs but some-
times also on the trunk. This is characteristic of AL amyloid, due to a plasma cell dis-
order in hematological malignancies. Primary systemic amyloidosis is due to a plasma 
cell dyscrasia, while secondary systemic amyloidosis arises from chronic inflammatory 
conditions such as rheumatoid arthritis or in the setting of chronic infections [67, 68].
Skin biopsy reveals accumulation of amyloid with characteristic staining (Congo 
red) properties under polarizing microscopic examination. Immunofixation of serum 
or urine is necessary for unambiguous identification of a monoclonal component [69].
Treatment of all forms of amyloidosis is challenging; although the primary 
cutaneous forms are not life-threatening, primary systemic amyloidosis can carry a 
poor prognosis for a patient [70].
12. Conclusion
Systemic sclerosis mimics include a variety of diseases that may resemble sys-
temic connective tissue diseases such as SSc. Above all, the most common diseases 
are discussed in this chapter.
The basis of proper diagnosis and treatment is the interdisciplinary collabora-
tion of rheumatology and dermatology with the possibility of biopsy tissue collec-
tion and histological verification of the disease.
A carefully performed clinical history and physical examination may distinguish 
these scleroderma mimic syndromes from systemic sclerosis (SSc, scleroderma) 
and from each other. The distribution and the quality/texture of skin involvement 
(in SSc typically: sclerodactyly, puffy fingers, ischemic defects/pitting scars/
digital ulcers/gangrenes, telangiectasias, calcinosis), the presence of Raynaud’s 
phenomenon (typically signs of a secondary Raynaud’s phenomenon such as onset 
after the age of 40, asymmetry, thumb involvement, ischemic pain, history of 
symptoms <3 years, worsening attacks) or abnormal nail fold capillary microscopy 
(characteristic scleroderma patterns in SSc), the presence and type of associated 
systemic manifestations (typical organ involvement characteristic for SSc), and the 
association with particular concurrent diseases or specific laboratory parameters 
(SSc-specific autoantibodies such as anti-topoisomerase I, anti-centromere, anti-
RNA-polymerase III) can be of substantial help in refining the diagnosis.
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In some cases, a full-thickness skin biopsy is helpful to confirm the clinical 
suspicion. Effective therapies are available for some of these conditions, whereas 
others are more refractory. For this reason, a prompt diagnosis is important to guide 
treatment decisions wisely, to spare the patients from ineffective treatments, to 
facilitate appropriate diagnostic evaluations, and to allow for accurate determina-
tion of prognosis [71].
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